Company

Vectivbio AG

Basel-based biopharmaceutical company founded in 2019 that develops therapies for gastrointestinal diseases and listed on Nasdaq.

About

Vectivbio AG, founded in 2019 as a spinoff and based in Basel, Switzerland, develops treatments for gastrointestinal diseases. The company raised USD 127.5 mn in an IPO on the Nasdaq in April 2021 and USD 30 mn in a private placement in June 2022. For 2021 it reported an EBITDA of USD -86.41 mn. It plans to use its funding to support the Phase III clinical program for its investigational products. Ironwood Pharmaceuticals, Inc. is a notable investor.

3Funding rounds

15Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in